Cytori Therapeutics Inc (NASDAQ: CYTX) is having an incredibly strong start to the trading session this morning, and for good reason. The company issued a PR early this morning informing investors that it has been issued key patents. Of course, this led to excitement among investors who are sending the stock upward as we speak. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (7:22), CYTX is trading at $1.10 per share after a gain of $0.09 per share or 8.91% thus far today.
CYTX Gains On Patent News
As mentioned above, Cytori Therapeutics is having a strong start to the trading session this morning after announcing that it has been issued key patents. As a result of the new patents issued, the company now boasts 107 global patents as well as 45 patent applications that are pending around the world. Here is a list of the newest patents that the company has been issued:
- July 5, 2017 – The European Patent Office issued a patent to CYTX on July 5th. This patent claims the use of Adipose-Derived Regenerative Cells, including Habeo™ Cell Therapy for the treatment of scleroderma, including the treatment of Raynaud’s Phenomenon or suppression of pain from Raynaud’s Phenomenon. The patent, Patent No. 3046417, will remain active through 2034.
- April 19, 2017 – On April 19th, the European Patent Office issued CYTX Patent No. 1670315. This patent claims the use of ADRCs, including Habeo™ Cell Therapy, to treat vascular disease. These are disorers that affect the blood carrying vessels of the body. This patent will remain active through 2024.
- December 6, 2016 – Finally, on December 6th, the United States Patent Office issued Patent No. 9511096. This patent covers the use of ADRCs, including Cytori Cell Therapy™, as a treatment for ischemic wounds. This patent will remain active until at least 2022.
In a statement, John D. Harris, Vice President and General Manager of Cell Therapy at CYTX, had the following to offer:
“Building on Cytori’s broad intellectual property portfolio continues to be a priority… Our intellectual property strategy is to continue to strengthen the Cytory Cell Therapy™ platform to help establish and maintain a substantial competitive advantage. Our main focus is on the primary therapeutic targets of scleroderma and Raynaud’s Phenomenon, though we will continue to seek additional intellectual property in other therapeutic areas as well.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on CYTX. In particular, we’re interested in following the ongoing work surrounding the company’s cell therapy as well as the IP news that continues to be released. We’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!